BioAtla (NASDAQ:BCAB) Given “Sell (D-)” Rating at Weiss Ratings

Weiss Ratings restated their sell (d-) rating on shares of BioAtla (NASDAQ:BCAB) in a report issued on Tuesday,Weiss Ratings reports.

Other equities research analysts have also recently issued reports about the stock. Citizens Jmp cut shares of BioAtla from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 13th. Wall Street Zen raised shares of BioAtla to a “sell” rating in a research report on Saturday, September 6th. Finally, JMP Securities reissued a “market perform” rating on shares of BioAtla in a research report on Wednesday, August 13th. Three investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Reduce”.

BioAtla Price Performance

BioAtla stock opened at $0.80 on Tuesday. BioAtla has a 12-month low of $0.24 and a 12-month high of $2.53. The stock has a market capitalization of $47.03 million, a P/E ratio of -0.73 and a beta of 1.03. The firm’s 50-day moving average is $0.58 and its two-hundred day moving average is $0.46.

BioAtla (NASDAQ:BCAB) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.02). As a group, analysts forecast that BioAtla will post -1.46 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of BCAB. Acadian Asset Management LLC raised its holdings in BioAtla by 968.9% in the first quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock valued at $585,000 after buying an additional 1,531,994 shares during the period. Acorn Capital Advisors LLC raised its holdings in BioAtla by 19.9% in the second quarter. Acorn Capital Advisors LLC now owns 4,835,111 shares of the company’s stock valued at $1,915,000 after buying an additional 803,065 shares during the period. Woodline Partners LP purchased a new position in BioAtla in the first quarter valued at approximately $26,000. Finally, Sheets Smith Investment Management purchased a new position in BioAtla in the third quarter valued at approximately $46,000. Hedge funds and other institutional investors own 77.23% of the company’s stock.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.